HRP20201197T1 - Upotreba kazeinskih pripravaka - Google Patents
Upotreba kazeinskih pripravaka Download PDFInfo
- Publication number
- HRP20201197T1 HRP20201197T1 HRP20201197TT HRP20201197T HRP20201197T1 HR P20201197 T1 HRP20201197 T1 HR P20201197T1 HR P20201197T T HRP20201197T T HR P20201197TT HR P20201197 T HRP20201197 T HR P20201197T HR P20201197 T1 HRP20201197 T1 HR P20201197T1
- Authority
- HR
- Croatia
- Prior art keywords
- casein
- calcium
- increasing
- depleted
- use according
- Prior art date
Links
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title claims 41
- 239000005018 casein Substances 0.000 title claims 40
- 235000021240 caseins Nutrition 0.000 title claims 40
- 239000000203 mixture Substances 0.000 title 1
- 102000011632 Caseins Human genes 0.000 claims 42
- 108010076119 Caseins Proteins 0.000 claims 42
- 239000011575 calcium Substances 0.000 claims 15
- 229910052791 calcium Inorganic materials 0.000 claims 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 13
- 238000002360 preparation method Methods 0.000 claims 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 8
- 210000002966 serum Anatomy 0.000 claims 8
- 102000014171 Milk Proteins Human genes 0.000 claims 4
- 108010011756 Milk Proteins Proteins 0.000 claims 4
- 229940071162 caseinate Drugs 0.000 claims 4
- 239000012141 concentrate Substances 0.000 claims 4
- 235000021239 milk protein Nutrition 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000005095 gastrointestinal system Anatomy 0.000 claims 3
- 230000007062 hydrolysis Effects 0.000 claims 3
- 238000006460 hydrolysis reaction Methods 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 230000026731 phosphorylation Effects 0.000 claims 3
- 238000006366 phosphorylation reaction Methods 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 238000011084 recovery Methods 0.000 claims 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 150000001669 calcium Chemical class 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000000693 micelle Substances 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 235000020183 skimmed milk Nutrition 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 235000008939 whole milk Nutrition 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- 102100035606 Beta-casein Human genes 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 101000947120 Homo sapiens Beta-casein Proteins 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102000008934 Muscle Proteins Human genes 0.000 claims 1
- 108010074084 Muscle Proteins Proteins 0.000 claims 1
- 239000005862 Whey Substances 0.000 claims 1
- 102000007544 Whey Proteins Human genes 0.000 claims 1
- 108010046377 Whey Proteins Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 235000019577 caloric intake Nutrition 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 235000019621 digestibility Nutrition 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000030136 gastric emptying Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 230000006362 insulin response pathway Effects 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- 229960003975 potassium Drugs 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229940080237 sodium caseinate Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 235000021249 α-casein Nutrition 0.000 claims 1
- 235000021246 κ-casein Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1422—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of milk, e.g. for separating protein and lactose; Treatment of the UF permeate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1427—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by dialysis, reverse osmosis or hyperfiltration, e.g. for concentrating or desalting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/146—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/202—Casein or caseinates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Water Supply & Treatment (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
Claims (15)
1. Upotreba kazeinskog pripravka u povećavanju koncentracije slobodnog leucina u krvnom serumu kod subjekta, naznačena time što kazeinski pripravak sadrži ili je kazein u obliku koncentrata ili izolata mliječnog proteina (MPC ili MPI) osiromašenog kalcijem, kazein je 10 do 100% osiromašen kalcijem, stupanj hidrolize mu je manji od 1% i ima nemodificirani uzorak fosforilacije; te što upotreba nije namijenjena provođenju terapije kod ljudskog ili životinjskog organizma.
2. Upotreba kazeinskog pripravka u povećavanju brzine pražnjenja želuca nakon ingestije pripravka, povećavanju probavljivosti proteinskog pripravka, ili povećavanju brzine unosa aminokiselina u krv, naznačena time što kazeinski pripravak sadrži ili je kazein u obliku koncentrata ili izolata mliječnog proteina (MPC ili MPI) osiromašenog kalcijem, kazein je 10 do 100% osiromašen kalcijem, stupanj hidrolize mu je manji od 1% i ima nemodificirani uzorak fosforilacije; te što upotreba nije namijenjena provođenju terapije kod ljudskog ili životinjskog organizma.
3. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što kazein povećava koncentraciju slobodnog leucina u krvnom serumu kod subjekta unutar 15, 30, 45 ili 60 minuta nakon primjene.
4. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što kazein može povećati koncentraciju slobodnog leucina u krvnom serumu to najmanje 205 do 400 µmol/l.
5. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što kazein može povećati koncentraciju slobodnog leucina u krvnom serumu to najmanje 205 µmol/l u trajanju od najmanje 5 do 50 minuta.
6. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što kazein može povećati koncentraciju slobodnog leucina u krvnom serumu za najmanje 105 do 400 µmol/l.
7. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što kazein može povećati koncentraciju slobodnog leucina u krvnom serumu za najmanje 105 µmol/l u trajanju od najmanje 5 do 50 minuta.
8. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što kazein ostaje topljiv kod pH od 1 do 5, ostaje topljiv u gastrointestinalnom sustavu, ostaje topljiv u gastrointestinalnom fluidu, ne tvori koagulum kod pH od 1 do 5, ili ne tvori koagulum u gastrointestinalnom sustavu.
9. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što kazein uglavnom ne sadrži vezani kalcij.
10. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što kazeinski pripravak sadrži kazeinski pripravak osiromašen kalcijem; obrano mlijeko osiromašeno kalcijem; obrano mlijeko u prahu osiromašeno kalcijem; puno mlijeko osiromašeno kalcijem; puno mlijeko u prahu osiromašeno kalcijem; kazeinat, natrijev kazeinat, kalijev kazeinat, cinkov kazeinat, magnezijev kazeinat; koncentrat ili izolat mliječnog proteina modificiran radi disociranja micela kazeina; nemicelarni kazein; kazeinski sastojak, poput MPC ili MPI, gdje su u najmanju ruku dio kalcija ili fosfata ili i kalcij i fosfat zamijenjeni natrijem, kalijem, cinkom, magnezijem i slično, ili kombinacija bilo koja dva ili više njih; kazein topljiv u kiselini; nemicelarni kazeinat; micele keliranog kazeina; kazein s modificiranim nabojem; glikozilirani kazein; kazein modificiran radi smanjivanja svoje sposobnosti stvaranja koaguluma kod kiselog pH, po mogućnosti kod pH ispod pH 5, pH 4 ili pH 3; kazein modificiran radi ubrzavanja svoje sposobnosti hidroliziranja u gastrointestinalnom sustavu; kazeinski sastojak s promijenjenim omjerom između kazeina i sirutke; kazein uz mliječnu kiselinu; kazein uz mineralnu kiselinu; jednu ili više frakcije kazeina; frakciju kazeina α; frakciju kazeina β; frakciju kazeina κ; ili bilo koju kombinaciju bilo koja dva ili više njih.
11. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je kazein stabilan kod pH od 1 do 5.
12. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što povećana koncentracija leucina u krvnom serumu rezultira bilo kojim ili više od sljedećeg:
a) održavanjem ili povećanjem sinteze mišićnih proteina,
b) održavanjem ili povećanjem mišićne mase,
c) sprječavanjem ili smanjivanjem gubitka mišićne mase,
d) održavanjem ili povećanjem rasta,
e) sprječavanjem ili smanjivanjem mišićnog katabolizma,
f) povećanjem stope resinteze glikogena,
g) moduliranjem razina šećera u krvi,
h) povećanim odgovorom inzulin na povišenu koncentraciju glukoze u krvi,
i) povećanjem sitosti,
j) smanjenjem zasićivanja,
k) smanjenjem unosa hrane,
l) smanjenjem unosa kalorija,
m) poboljšanjem metabolizma glukoze,
n) povećanjem brzine oporavka nakon fizičke aktivnosti, ili
o) povećanjem radnog učinka u sportovima.
13. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što pripravak sadrži najmanje 0,01 do 99%, težinski, kazeina, ili što pripravak sadrži 0,01 do 99%, težinski, proteina, a protein sadrži 0,01 do 99%, težinski, kazeina.
14. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što kazein sadrži 0 do 3 g kalcija/100 g kazeina.
15. Kazeinski pripravak, naznačen time što je namijenjen upotrebi u a) sprječavanju ili liječenju kaheksije kod subjekta, b) sprječavanju ili liječenju sarkopenije kod subjekta, c) povećavanju brzine oporavka nakon kirurškog zahvata kod subjekta, ili d) povećavanju brzine oporavka nakon ozljede kod subjekta, povećavanjem koncentracije slobodnog leucina u krvnom serumu kod subjekta;
gdje je kazein 10 do 100% osiromašen kalcijem, stupanj hidrolize mu je manji od 1% i ima nemodificirani uzorak fosforilacije; i
gdje kazeinski pripravak sadrži ili je kazein u obliku koncentrata ili izolata mliječnog proteina (MPC ili MPI) osiromašenog kalcijem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608858P | 2012-03-09 | 2012-03-09 | |
| PCT/NZ2013/000035 WO2013133727A1 (en) | 2012-03-09 | 2013-03-11 | Uses of casein compositions |
| EP13757439.8A EP2822568B1 (en) | 2012-03-09 | 2013-03-11 | Uses of casein compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201197T1 true HRP20201197T1 (hr) | 2020-11-13 |
Family
ID=49117099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201197TT HRP20201197T1 (hr) | 2012-03-09 | 2020-07-30 | Upotreba kazeinskih pripravaka |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20150011468A1 (hr) |
| EP (1) | EP2822568B1 (hr) |
| JP (1) | JP6420156B2 (hr) |
| CN (1) | CN104159592B (hr) |
| AU (1) | AU2013202942B2 (hr) |
| DK (1) | DK2822568T3 (hr) |
| ES (1) | ES2811759T3 (hr) |
| HK (1) | HK1205947A1 (hr) |
| HR (1) | HRP20201197T1 (hr) |
| HU (1) | HUE050010T2 (hr) |
| LT (1) | LT2822568T (hr) |
| NZ (1) | NZ700686A (hr) |
| PL (1) | PL2822568T3 (hr) |
| WO (1) | WO2013133727A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201601999UA (en) * | 2013-09-25 | 2016-04-28 | Pronutria Inc | Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control |
| US20170347680A1 (en) * | 2014-12-26 | 2017-12-07 | Compagnie Gervais Danone | Process for making a viscous composition comprising whey protein |
| CA2986889C (en) * | 2015-05-22 | 2023-08-29 | The A2 Milk Company Limited | Beta-casein a2 and antioxidant capacity |
| TWI761487B (zh) * | 2017-04-06 | 2022-04-21 | 日商明治股份有限公司 | 用於促進血中胺基酸濃度上升之發酵乳 |
| AU2018361465A1 (en) | 2017-10-30 | 2020-03-12 | Frieslandcampina Nederland B.V. | Protein-dense nutritional compositions for use in treating and/or preventing a condition linked to loss of muscle mass and/or strength |
| JP7292012B2 (ja) | 2018-06-14 | 2023-06-16 | 株式会社クボタ | コンバイン |
| JPWO2021210539A1 (hr) * | 2020-04-13 | 2021-10-21 | ||
| US20210352938A1 (en) * | 2020-05-12 | 2021-11-18 | Raymond L. Sullivan, JR. | Novel drink |
| JP7282061B2 (ja) | 2020-06-25 | 2023-05-26 | 株式会社クボタ | コンバイン |
| US20220030923A1 (en) * | 2020-07-17 | 2022-02-03 | Northern Innovations Holding Corp. | Caffeine and Alpha Lipoic Acid Compositions for Enhanced Sensory Effects |
| US20220225640A1 (en) * | 2021-01-19 | 2022-07-21 | Alexia Ramos | Multipurpose Beverage Composition |
| EP4326091A1 (en) * | 2021-04-19 | 2024-02-28 | Abbott Laboratories | High protein liquid nutritional compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ501676A (en) * | 1999-12-09 | 2002-12-20 | New Zealand Dairy Board | Calcium-depleted milk protein products and use in cheese manufacture to reduce nugget-formation |
| NZ501675A (en) * | 1999-12-09 | 2002-12-20 | New Zealand Dairy Board | Translucent milk drink having a pH of 5.7 to 7.0 and a percentage transmission of at least 5% prepared by a cation exchange process |
| US6592863B2 (en) * | 2000-08-22 | 2003-07-15 | Nestec S.A. | Nutritional composition |
| US20040087490A1 (en) * | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
| NZ523394A (en) * | 2002-12-24 | 2006-03-31 | New Zealand Dairy Board | Dairy protein processing and applications thereof |
| WO2010126353A1 (en) | 2009-04-27 | 2010-11-04 | N.V. Nutricia | Pea-based protein mixture and use thereof in a liquid nutritional composition suitable for enteral feeding |
| EP2792251B2 (en) * | 2010-01-29 | 2022-08-31 | Abbott Laboratories | Nutritional emulsions comprising calcium HMB and soluble protein |
| HUE057338T2 (hu) | 2010-07-16 | 2022-05-28 | Fonterra Cooperative Group Ltd | Tejtermék és eljárás |
-
2013
- 2013-03-11 CN CN201380013026.3A patent/CN104159592B/zh active Active
- 2013-03-11 ES ES13757439T patent/ES2811759T3/es active Active
- 2013-03-11 HU HUE13757439A patent/HUE050010T2/hu unknown
- 2013-03-11 LT LTEP13757439.8T patent/LT2822568T/lt unknown
- 2013-03-11 PL PL13757439T patent/PL2822568T3/pl unknown
- 2013-03-11 EP EP13757439.8A patent/EP2822568B1/en active Active
- 2013-03-11 JP JP2014560887A patent/JP6420156B2/ja active Active
- 2013-03-11 US US14/382,266 patent/US20150011468A1/en not_active Abandoned
- 2013-03-11 WO PCT/NZ2013/000035 patent/WO2013133727A1/en active Application Filing
- 2013-03-11 AU AU2013202942A patent/AU2013202942B2/en active Active
- 2013-03-11 DK DK13757439.8T patent/DK2822568T3/da active
- 2013-03-11 NZ NZ700686A patent/NZ700686A/en unknown
-
2015
- 2015-07-10 HK HK15106582.4A patent/HK1205947A1/xx unknown
-
2017
- 2017-01-31 US US15/421,245 patent/US20170232063A1/en not_active Abandoned
-
2018
- 2018-12-10 US US16/214,771 patent/US20190105371A1/en active Pending
-
2020
- 2020-07-30 HR HRP20201197TT patent/HRP20201197T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104159592B (zh) | 2018-10-19 |
| WO2013133727A1 (en) | 2013-09-12 |
| CN104159592A (zh) | 2014-11-19 |
| DK2822568T3 (da) | 2020-08-10 |
| JP6420156B2 (ja) | 2018-11-07 |
| NZ700686A (en) | 2016-08-26 |
| AU2013202942A1 (en) | 2013-09-26 |
| EP2822568A1 (en) | 2015-01-14 |
| US20170232063A1 (en) | 2017-08-17 |
| JP2015509531A (ja) | 2015-03-30 |
| US20190105371A1 (en) | 2019-04-11 |
| US20150011468A1 (en) | 2015-01-08 |
| LT2822568T (lt) | 2020-09-10 |
| HK1205947A1 (en) | 2015-12-31 |
| ES2811759T3 (es) | 2021-03-15 |
| EP2822568A4 (en) | 2015-11-11 |
| EP2822568B1 (en) | 2020-06-17 |
| HUE050010T2 (hu) | 2020-11-30 |
| AU2013202942B2 (en) | 2016-05-12 |
| PL2822568T3 (pl) | 2020-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201197T1 (hr) | Upotreba kazeinskih pripravaka | |
| CN101248900B (zh) | 一种新型固体运动饮料冲剂 | |
| JP4291513B2 (ja) | 身体的作業能力改善用組成物 | |
| CN105145846A (zh) | 一种提高骨密度，改善骨质疏松的营养包 | |
| CN103369975A (zh) | 具有减少的涩味的乳清蛋白组合物 | |
| JP6758285B2 (ja) | 乳清タンパク質ミセルとペクチンの複合体及び身体筋肉タンパク質合成 | |
| CN105658231A (zh) | 肌肉合成促进剂 | |
| Sakandar et al. | Camel milk and its allied health claims: A review | |
| AU2019384948B2 (en) | Dairy product and process | |
| AU2013202191A1 (en) | Micronutrient Fortification Process and its Uses | |
| JPH09124473A (ja) | 体力増強剤 | |
| Framroze et al. | Comparison of nitrogen bioaccessibility from salmon and whey protein hydrolysates using a human gastrointestinal model (TIM-1) | |
| TWI620509B (zh) | 飲料之用途及其製造方法 | |
| CN107517585A (zh) | 抑制运动时的心率上升的方法和抑制心率上升的组合物 | |
| WO2014125099A1 (en) | Food composition and its use | |
| JPS59210872A (ja) | 飲料組成物 | |
| US9211297B2 (en) | Exercise performance-increasing nutritional supplement and related methods and compositions | |
| CN101209084A (zh) | 一种含有活性肽的宠物饮料及其制备方法 | |
| JP2002281941A (ja) | 高カルシウム含有食品調合物 | |
| Krüger et al. | Trabajo Original Otros | |
| US20220313729A1 (en) | Amorphous calcium carbonate for improving athletic performance | |
| RU2183930C2 (ru) | Сухой молочно-белковый продукт "биопротеин" | |
| Luotonen | Effects of carbohydrate content on body composition during weight loss in female fitness competitors | |
| Volpe | Calcium, zinc, iron, and exercise in women | |
| WO2018189320A1 (en) | A composition with mobility benefits in ageing, healthy subjects |